Kay Day is right and other KnownsPatent Issuance is vital...
Kay Day nailed it with her assessment of the value of a 'Patent Pending' status.
I am not a patent lawyer
either but it seems to me that this means that you have staked a claim. You have identified your regimen or product and you have explained it to he detailed extent that the Patent Office can determine that it is in fact, novel and 'yours' rather than a derivative or a copy of someone else, who came before you. Having someone else come forward and essentially try to copy your work or reverse engineer your product after you have filed it and it is 'Pending' means that they can be forced to cease and desist, and pay YOU their earnings for stealing your idea or for not registering it first. If a competing stem cell company is trying to come up with the formula and are just taking stabs in the dark hoping to replicate the results, they may waste millions for nothing if the patent ultimately is granted to the company with that patent in a 'pending' state. Even if they arrive at the same combination by chance and have the weight of huge pharma budgets behind them, they cannot take your Pending patent from you.
Having the Patent Issued means confirmation that YES, you have a novel approach here.
Furthermore, it means that NO, nobody else can come in and try to do the exact same thing and legitimately profit from it because the original patent holder has the the protection in place
----------NEXT Why this really great.----------The meeting in Calgary allowed us a glimpse into the idea that lay ahead.
The NTX protocols are not so much different in formulation as they are different in application.We heard them say that it is a 'product approach' rather than a treatment approach.
NTX, once proven, is a product that can be deployed against many CNS/Brain issues.
It is stimulation of resident stem cells to create more brain tissue.
It is a 'master key' approach that, if you will, creates an environment where brain tissue grows and regenerates to fill the need. Maybe the need is stroke damage repair, maybe it is TBI repair, maybe it is ALS repair and reversal... or MS Repair...or?
If we can get definitively get the proof that the NTX regimen grows useful, viable brain cells, then all that needs to be proven is if it will grow the types of cells in the necessary areas of the brain where the disease or damage exists.
Note that in the release we are covered on all fronts and if this does, in fact, serve as a 'master key' then the different trials (TBI, Stroke, etc) are proving application, not formuation. This Patent Issuance allows us to 'circle the wagons' and protect this piece of IP that may be the most vital piece in the SCT puzzle.
Here is an excerpt from the recent release.
Now read it again and see if it excites you any more!
The covered in vivo uses include administration of these compounds to subjects having neurodegenerative conditions, diseases and CNS injuries. This is the first U.S. patent to issue in this patent family and it protects the use of the NTx®-265 regimen in the acute neurologic injury indications of Stroke, and Traumatic Brain Injury, amongst other indications. Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows:
"We at SCT are very excited to see this patent issue as it represents an important intellectual property milestone for the NTx®-265 program. This patent offers protection and support for our NTx®-265 technology, a keystone patent, while expanding and increasing value to SCT's overall intellectual property portfolio."
HnG